Hi, 'Mom'! James Webb telescope discovers MoM-z14 — the most distant, early galaxy ever seen
When you buy through links on our articles, Future and its syndication partners may earn a commission.
The James Webb Space Telescope (JWST) has spotted the most distant galaxy observed to date — breaking its own record yet again.
The galaxy, dubbed MoM-z14, is "the most distant spectroscopically confirmed source to date, extending the observational frontier to a mere 280 million years after the Big Bang," researchers wrote in a new study that appeared May 23 on the preprint server arXiv.
In other words, the galaxy emitted light just 280 million years after the birth of the universe; after its long journey across the cosmos, that light is only now reaching Earth and JWST's infrared sensors.
"It's pretty exciting," Charlotte Mason, an astrophysicist at the University of Copenhagen who wasn't involved in the study, told New Scientist. "It confirms that there really are these very bright galaxies in the universe."
Since beginning operation in 2022, JWST has spotted more bright, ancient galaxies than scientists expected, challenging previous theories about the universe's infancy. "This unexpected population has electrified the community and raised fundamental questions about galaxy formation in the first 500 [million years after the Big Bang]," the authors wrote.
As more examples trickle in, scientists are working to confirm whether these luminous objects really are ancient galaxies. Study lead author Rohan Naidu, an astrophysicist at MIT, and colleagues combed through existing JWST images for potential early galaxies to check. After identifying MoM-z14 as a possible target, they turned the telescope toward the peculiar object in April 2025.
One way scientists can measure an astronomical object's age is by measuring its redshift. As the universe expands, it stretches the light emitted by distant objects to longer, "redder" wavelengths. The farther and longer the light has traveled, the larger its redshift. In the new study, which has not yet been peer-reviewed, the team confirmed MoM-z14's redshift as 14.44 — larger than that of the previous record holder for farthest observed galaxy, JADES-GS-z14-0, at 14.18.
Related: James Webb telescope sees 'birth' of 3 of the universe's earliest galaxies in world-1st observations
MoM-z14 is fairly compact for the amount of light it emits. It's about 240 light-years across, some 400 times smaller than our own galaxy. And it contains about as much mass as the Small Magellanic Cloud, a dwarf galaxy that orbits the Milky Way.
RELATED STORIES
—James Webb telescope spots Milky Way's long-lost 'twin' — and it is 'fundamentally changing our view of the early universe'
—'I was astonished': Ancient galaxy discovered by James Webb telescope contains the oldest oxygen scientists have ever seen
—'Totally unexpected' galaxy discovered by James Webb telescope defies our understanding of the early universe
The researchers observed MoM-z14 during a burst of rapid star formation. It's also rich in nitrogen relative to carbon, much like globular clusters observed in the Milky Way. These ancient, tightly-bound groups of thousands to millions of stars are thought to have formed in the first few billion years of the universe, making them the oldest known stars in the nearby cosmos. That MoM-z14 appears similar could suggest that stars formed in comparable ways even at this very early stage in the universe's development.
Though scientists still aim to confirm more high redshift galaxies, researchers expect to find even more candidates with the Nancy Grace Roman Space Telescope, an infrared telescope designed to observe a large swath of the sky, which is set to launch by May 2027.
But JWST may break its own record again before then. "JWST itself appears poised to drive a series of great expansions of the cosmic frontier," the authors wrote. "Previously unimaginable redshifts, approaching the era of the very first stars, no longer seem far away."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
2 hours ago
- Washington Post
In Poland's golden hour, a looming threat to Europe's unity
KRAKOW, Poland — In this golden moment of Polish history, why do so many Poles see the future as fraught, grim, even dangerous? Across Europe's newest economic powerhouse, where living standards have leapfrogged Japan's and are on course to surpass Spain's and Israel's, incomes are surging, shops are buzzing and borders are secure — at least for now.
Yahoo
3 hours ago
- Yahoo
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ('Cartesian' or the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. 'With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG,' said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. 'With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.' 'Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate,' said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. 'Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study.' The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo. In April 2025, the Company announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with MG. After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in the MG-ADL score at Month 12. The deepest and most compelling sustained responses were observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. The safety profile of Descartes-08 was consistent with previously reported data and continues to support outpatient administration. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Forward Looking Statements Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding observations and data from the Company's clinical trials, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the ability of the Company's product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, Descartes-15, or any of the Company's other product candidates to treat myasthenia gravis, systemic lupus erythematosus, juvenile dermatomyositis, multiple myeloma, or any other disease, the anticipated timing or the outcome of the FDA's review of the Company's regulatory filings, the Company's ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company's clinical trials and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'hypothesize,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial, whether results of early clinical trials will be indicative of the results of later clinical trials, and whether results observed in certain patient subgroups will be indicative of the results in such subgroups in later clinical trials or are reflective of a product candidate's overall characteristics, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company's technology, potential delays in enrollment of patients, undesirable side effects of the Company's product candidates, its reliance on third parties to conduct its clinical trials, the Company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company's recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company's common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the 'Risk Factors' section of the Company's most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward looking statements included in this press release, except as required by law. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Media Contact:David RosenArgot in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data